Lung Function

Dupilumab’s impact on exacerbation rate and lung function in adults with COPD and type 2 inflammation did not differ based on BODE index score, according to a poster presented at the European Respiratory Society International Congress.

Adults with idiopathic pulmonary fibrosis met the primary endpoint of absolute change in FVC with 52-week oral nerandomilast, an investigational phosphodiesterase 4B inhibitor, vs. placebo, according to FIBRONEER-IPF topline results.

Dupilumab led to improvement and was safe in adults with moderate to severe COPD and type 2 inflammation at week 52, according to a pooled analysis of BOREAS and NOTUS presented at the European Respiratory Society International Congress.

Patients with severe emphysema had lasting lung function improvement 5 years after bronchoscopic lung volume reduction with Zephyr Valves, according to a poster presented at the European Respiratory Society International Congress.

Four variables, including chronic bronchitis and high symptom burden, heightened the rate of exacerbations among patients with COPD and no recent exacerbations, according to results published in Annals of the American Thoracic Society.

With just chest X-rays, an AI model estimated FVC and FEV1 and had “excellent agreement” when compared with spirometry results, according to results published in The Lancet Digital Health.

Following use of race-neutral vs. -specific lung function equations, spirometry findings and patterns differed, especially among Black children/adolescents, according to results published in JAMA Pediatrics.

Patients with non-cystic fibrosis bronchiectasis experienced less FEV1 and FVC decline and had improved quality of life with 52-week once-daily brensocatib vs. placebo, according to findings presented at the World Bronchiectasis Conference.

SAN DIEGO — After bronchoscopic lung volume reduction, or BLVR, patients with COPD and alpha-1 antitrypsin deficiency had better lung function, according to a poster at the American Thoracic Society International Conference.

Among patients with idiopathic pulmonary fibrosis, 12-week bexotegrast was deemed well tolerated and may have an antifibrotic effect, according to results published in American Journal of Respiratory and Critical Care Medicine.